Ostac (Clodronate Disodium Tetrahydrate)

Clodronate disodium tetrahydrate, the active ingredient in Ostax, is a bis‑bisphosphonate presented as a solid oral dosage form for systemic use. It is employed in the management of bone‑related conditions, particularly those involving increased bone turnover such as osteoporosis and bone metastases in adult patients.

GNH USA supplies Ostac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Clodronate disodium tetrahydrate is a bis‑bisphosphonate that acts on bone metabolism pathways to reduce skeletal complications. - Osteoporosis: helps reduce the risk of vertebral and non‑vertebral fractures in post‑menopausal women and older men. - Paget’s disease of bone: normalises elevated bone turnover markers and alleviates bone pain. - Bone metastases: decreases skeletal‑related events such as pathological fractures and the need for radiotherapy in patients with solid‑tumour metastases. - Hypercalcaemia of malignancy: assists in lowering serum calcium levels associated with malignant disease.

Clodronate disodium tetrastrength ...